StockNews.AI
CRVS
StockNews.AI
155 days

Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

1. Corvus Pharmaceuticals will host a conference call on March 25, 2025. 2. The call will report Q4 and full-year 2024 financial results. 3. The company focuses on ITK inhibition for cancer treatment. 4. Soquelitinib is their lead investigational drug candidate. 5. A webcast replay will be available for 90 days.

Earnings
-0.64%Current Return
VS
-1.06%S&P 500
$4.7203/17 04:05 PM EDTEvent Start
$4.6903/18 10:31 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

Upcoming financial results announcement could raise investor confidence and interest. Historically, calls of this nature can lead to price increases, especially if results meet or exceed expectations.

How important is it?

The call could provide insights into financial health, impacting investor sentiment significantly. As CRVS is a clinical-stage company, updates are critical for valuation.

Why Short Term?

Financial results and business updates typically influence stock prices immediately or within days. If positive, it can boost confidence leading to short-term upward movement.

Related Companies

IMTXNKKRTX
Company to host conference call and webcast at 4:30 pm ET / 1:30 pm PT March 17, 2025 16:01 ET  | Source: Corvus Pharmaceuticals, Inc. SOUTH SAN FRANCISCO, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the company will host a conference call and webcast on March 25, 2025 at 4:30 pm ET (1:30 pm PT) to provide a business update and report fourth quarter and full year 2024 financial results. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 90 days. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of cancer and immune diseases. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com. INVESTOR CONTACT:Leiv LeaChief Financial OfficerCorvus Pharmaceuticals, Inc.+1-650-900-4522llea@corvuspharma.com MEDIA CONTACT:Sheryl SeapyReal Chemistry+1-949-903-4750sseapy@realchemistry.com

Related News